Proposed Collection; 60-Day Comment Request, National Institute on Drug Abuse (NIDA) Summer Research Internship Program, 64068-64069 [2022-22960]
Download as PDF
<![CDATA[
jspears on DSK121TN23PROD with NOTICES
64068
Federal Register / Vol. 87, No. 203 / Friday, October 21, 2022 / Notices
activities on behalf of the Secretary of
the U.S. Department of Health and
Human Services (HHS), with the
exception of the regulatory research
integrity activities of the Food and Drug
Administration. ORI is a program office
within the Office of the Assistant
Secretary for Health, Office of the
Secretary, HHS.
Core to ORI’s mission is the support
of education and outreach activities that
aid PHS-funded research institutions in
their efforts ‘‘to teach the responsible
conduct of research, promote research
integrity, prevent research misconduct,
and . . . to respond effectively to
allegations of research misconduct’’ (65
FR 30600, 30601 (May 12, 2000)). ORI
Events contribute to this mission by
providing education, training, and/or
the opportunity for discussion related to
topics such as handling allegations of
research misconduct and fostering
research integrity and the responsible
conduct of research. ORI Events
typically are moderately sized, usually
accepting between 20 and 150
attendees, and convened in person or
virtually for one to three days.
Co-sponsors will work with ORI staff
to jointly develop an event. Both ORI
and the co-sponsor must contribute
substantively to the development of the
event. Co-sponsors can charge
registration fees to recover costs
associated with the events; however, cosponsors may not set registration fees at
an amount higher than necessary to
recover event-related expenses. Further,
co-sponsors are solely responsible for
collecting and handling any registration
fees.
Eligibility for Co-Sponsorship: The cosponsoring entity must have
demonstrated interest and experience in
fostering the responsible conduct of
research or handling of research
misconduct allegations. The cosponsoring entity must participate
substantively in the co-sponsored
activity, and not just provide funding,
logistical services, or other material
support.
Expression of Interest in CoSponsorship: An entity shall provide an
expression of interest that includes (1)
one to two paragraphs detailing why
ORI should select the entity, including
the entity’s leadership in and
management of matters involving
research integrity and the responsible
conduct of research, and (2) a bulleted
outline addressing the seven topics
listed below. The expression of interest
should be one to two pages in length,
single-spaced, and at least 11-point font.
An entity may submit an expression of
interest individually or jointly with
other entities describing their relative
VerDate Sep<11>2014
19:08 Oct 20, 2022
Jkt 259001
contributions. The seven topics to be
addressed in the outline are:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
1. The entity’s interest and goals in
promoting research integrity and/or
the responsible conduct of research
2. The entity’s prior experience and
current readiness to undertake the
responsibilities described above
3. The type of event(s) that the entity is
interested in co-sponsoring with ORI
4. Facilities available for the event(s),
including the distance from the
facilities to a major airport
5. Any current constraints with respect
to dates or facilities
6. Whether the entity has co-sponsored
an ORI Event in the past 36 months
7. Whether the entity has any cases,
allegations, or other related matters
pending with ORI
National Institutes of Health
Evaluation Criteria: After engaging in
exploratory discussions with potential
co-sponsors who respond to this notice,
HHS will apply the following
considerations, as appropriate and
relevant, to select the co-sponsor(s):
• Qualifications and capability to fulfill
co-sponsorship responsibilities
• Suitability of the location of the
proposed event in terms of the overall
geographical distribution of recent or
planned ORI Events
• Potential for reaching, generating, and
engaging an adequate number of
attendees
• Availability and description of
facilities needed to support the event
• Availability of administrative support
for the logistics of hosting such events
The duties of the co-sponsor will be
outlined in a co-sponsorship agreement
with ORI that will set forth the details
of the co-sponsored event, including the
requirements that any fees collected by
the co-sponsor shall be limited to the
amount necessary to cover the cosponsor’s event-related expenses. This
co-sponsorship agreement does not
represent an endorsement by ORI of an
individual co-sponsor’s policies,
positions, or activities.
Dated: October 13, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity,
Office of the Assistant Secretary for Health.
[FR Doc. 2022–22887 Filed 10–20–22; 8:45 am]
BILLING CODE 4150–31–P
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
Proposed Collection; 60-Day Comment
Request, National Institute on Drug
Abuse (NIDA) Summer Research
Internship Program
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects, the
National Institute on Drug Abuse
(NIDA) will publish periodic summaries
of proposed projects to be submitted to
the Office of Management and Budget
(OMB) for review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
SUMMARY:
To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Dr. Wilson Compton, Acting
Director, Office of Research Training,
Diversity, and Disparities, National
Institute on Drug Abuse, 3WFN, 11601
Landsdown St., Room 09D18, North
Bethesda, Maryland, 20892 or call nontoll-free number (301) 443–6480 or
Email your request, including your
address, to: Wilson.Compton@nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
FOR FURTHER INFORMATION CONTACT:
Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires written
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimizes
the burden of the collection of
information on those who are to
respond, including the use of
SUPPLEMENTARY INFORMATION:
E:\FR\FM\21OCN1.SGM
21OCN1
64069
Federal Register / Vol. 87, No. 203 / Friday, October 21, 2022 / Notices
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Proposed Collection Title: NIDA
Summer Research Internship Program,
0925–0738, Expiration 12/31/2022,
EXTENSION, National Institute on Drug
Abuse (NIDA), National Institutes of
Health (NIH).
Need and Use of Information
Collection: The purpose of the proposed
information is for the selection of
interns for the continuing NIDA
Summer Research Internship Program.
interest in substance abuse research,
future career goals, and, if selected for
the program, what research they prefer
to conduct. The information also
enables decision-making regarding
which applicants will be selected for
internships. In each case, completing
the application is voluntary, but in
order to receive due consideration, the
prospective applicant must complete all
fields required by the program. OMB
approval is requested for 3 years. There
are no costs to respondents other than
their time. The total estimated
annualized burden hours are 300.
This request is to allow NIDA to collect
information from applicants in order to
meet the goals of the program and IC
mission. Applicant eligibility for this
program is for those age 18 and over in
the year of application per NIH policy
document.
NIDA Summer Research Internship
Program (NIDA–SIP) Policy. NIDA will
request clearance for any additional
forms should new programs be
introduced in the future.
The information ensures that students
applying to this program meet basic
eligibility requirements; indicates their
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Average
burden per
response
(in hours)
Estimated
total annual
burden hours
Type of respondent
Summer Internship ............................
Individuals-household .......................
300
1
1
300
Total ...........................................
...........................................................
........................
300
........................
300
Dated: October 18, 2022.
Lanette A. Palmquist,
Project Clearance Liaison, National Institute
on Drug Abuse, National Institutes of Health.
[FR Doc. 2022–22960 Filed 10–20–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
jspears on DSK121TN23PROD with NOTICES
Number of
respondents
Form
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Population and Public Health Approaches to
HIV/AIDS Study Section.
Date: November 14–15, 2022.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
19:08 Oct 20, 2022
Jkt 259001
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW,
Washington, DC 20015.
Contact Person: Jose H. Guerrier, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5222,
MSC 7852, Bethesda, MD 20892, 301–435–
1137, guerriej@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Musculoskeletal, Orthopedic, Oral,
Dermatology and Rheumatology.
Date: November 15–16, 2022.
Time: 8:30 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Aftab A. Ansari, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4108,
MSC 7814, Bethesda, MD 20892, (301) 237–
9931, ansaria@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Drug Discovery Involving the
Nervous System.
Date: November 15–16, 2022.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lai Yee Leung, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1011D,
Bethesda, MD 20892, (301) 827–8106,
leungl2@csr.nih.gov.
Name of Committee: Infectious Diseases
and Immunology B Integrated Review Group;
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
HIV Comorbidities and Clinical Studies
Study Section.
Date: November 15–16, 2022.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20876
(Virtual Meeting).
Contact Person: David C. Chang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 451–0290, changdac@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–RM–
22–024: Pilot Projects Investigating
Understudied G Protein-Coupled Receptors,
Ion Channels, and Protein Kinases.
Date: November 15–16, 2022.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Vandana Kumari, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 496–3290,
vandana.kumari@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Virology.
Date: November 15–16, 2022.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sharon Isern, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 810J,
E:\FR\FM\21OCN1.SGM
21OCN1
]]>Agencies
[Federal Register Volume 87, Number 203 (Friday, October 21, 2022)]
[Notices]
[Pages 64068-64069]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-22960]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment Request, National Institute
on Drug Abuse (NIDA) Summer Research Internship Program
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the requirement of the Paperwork Reduction
Act of 1995 to provide opportunity for public comment on proposed data
collection projects, the National Institute on Drug Abuse (NIDA) will
publish periodic summaries of proposed projects to be submitted to the
Office of Management and Budget (OMB) for review and approval.
DATES: Comments regarding this information collection are best assured
of having their full effect if received within 60 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data
collection plans and instruments, submit comments in writing, or
request more information on the proposed project, contact: Dr. Wilson
Compton, Acting Director, Office of Research Training, Diversity, and
Disparities, National Institute on Drug Abuse, 3WFN, 11601 Landsdown
St., Room 09D18, North Bethesda, Maryland, 20892 or call non-toll-free
number (301) 443-6480 or Email your request, including your address,
to: [email protected]. Formal requests for additional plans and
instruments must be requested in writing.
SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires written comments and/or suggestions from
the public and affected agencies are invited to address one or more of
the following points: (1) Whether the proposed collection of
information is necessary for the proper performance of the function of
the agency, including whether the information will have practical
utility; (2) The accuracy of the agency's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) Ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) Ways
to minimizes the burden of the collection of information on those who
are to respond, including the use of
[[Page 64069]]
appropriate automated, electronic, mechanical, or other technological
collection techniques or other forms of information technology.
Proposed Collection Title: NIDA Summer Research Internship Program,
0925-0738, Expiration 12/31/2022, EXTENSION, National Institute on Drug
Abuse (NIDA), National Institutes of Health (NIH).
Need and Use of Information Collection: The purpose of the proposed
information is for the selection of interns for the continuing NIDA
Summer Research Internship Program. This request is to allow NIDA to
collect information from applicants in order to meet the goals of the
program and IC mission. Applicant eligibility for this program is for
those age 18 and over in the year of application per NIH policy
document.
NIDA Summer Research Internship Program (NIDA-SIP) Policy. NIDA
will request clearance for any additional forms should new programs be
introduced in the future.
The information ensures that students applying to this program meet
basic eligibility requirements; indicates their interest in substance
abuse research, future career goals, and, if selected for the program,
what research they prefer to conduct. The information also enables
decision-making regarding which applicants will be selected for
internships. In each case, completing the application is voluntary, but
in order to receive due consideration, the prospective applicant must
complete all fields required by the program. OMB approval is requested
for 3 years. There are no costs to respondents other than their time.
The total estimated annualized burden hours are 300.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden Estimated
Form Type of Number of responses per per response total annual
respondent respondents respondent (in hours) burden hours
----------------------------------------------------------------------------------------------------------------
Summer Internship............. Individuals- 300 1 1 300
household.
---------------------------------------------------------------
Total..................... ................ .............. 300 .............. 300
----------------------------------------------------------------------------------------------------------------
Dated: October 18, 2022.
Lanette A. Palmquist,
Project Clearance Liaison, National Institute on Drug Abuse, National
Institutes of Health.
[FR Doc. 2022-22960 Filed 10-20-22; 8:45 am]
BILLING CODE 4140-01-P
